Should Dentists be Allowed to Administer Botulinum Toxin?

Brion Benninger1,2,3 and Alan Ross1,2

1Departments of Medical Anatomical Sciences, College of Dental Medicine, Western University of Health Sciences, Lebanon
2College of Dental Medicine, Western University of Health Sciences, Samaritan Health Services, Orthopaedic and General Surgery Residency Faculty, Lebanon & Corvallis
3Departments of Oral Maxillofacial Surgery, Surgery, and Orthopaedic Surgery, Oregon Health & Science University, Portland

Abstract

Purpose: The purpose of this study was to investigate why dentists should be allowed to administer botulinum toxin (BoNTA). There are several common pathologies that occur in dentistry that BoNTA could be used to alleviate.

Introduction: Pathology resulting from improper clenching and impact force by muscles of mastication are significant issues faced by dentists. Many techniques used for the treatment of these pathologies are expensive, invasive for the patient, and may be ineffective. BoNTA inhibits acetylcholine release, blocking or reducing the contraction of muscles which can have a positive outcome for patients with increased muscle spasm, temporomandibular joint pathologies, bruxism, trismus, tolerance of intra-oral prostheses and other oral conditions.

Methods: A literature search of texts, journals and websites was conducted for BoNTA and its use in dentistry. We analyzed the basic science and clinical curriculum of 20 dental and medical healthcare training institutions.

Results: Today’s dentists are prepared to administer BoNTA because of their extensive head and neck anatomical training, pharmacology and the experience acquired from thousands of clinical injections.

Conclusion: Currently, the American Dental Association has not taken a position on the administration of BoNTA by dentists; however, several Dental State Boards have developed, or are developing a policy for its use. This study proposes that dentists should be allowed to inject BoNTA based on their didactic and clinical anatomy courses and clinical curriculum. BoNTA is an effective treatment for oral pathologies.
Methods

A literature search of texts, journals and websites was conducted for BoNTA and its use in dentistry. PubMed was initially used for the literature search, and this was followed up with a literature search using Google Scholar. The specific terms search were “botulinum toxin,” “botox,” “dentistry and botox,” “head, face and botox,” “oral maxillofacial surgery and botox.” We analyzed the basic science and clinical curriculum of 20 dental and medical healthcare training institutions, which were chosen at random. There was no funding for this study.

Results

Textbooks and journal articles revealed multiple uses for BoNTA therapy in treating intra and extra oral pathologies. Results from investigating basic science curriculum and clinical skill instruction, revealed excellent practice, and suggested that dental training safely prepared trainees to administer BoNTA. Generally, dentists receive an accelerated clinical anatomy course below the head and neck and an 11 to 12 week specific course of head and neck anatomy compared to their medical colleagues who receive on average 2 to 3 weeks of head and neck anatomy education during their first 4 years of prequalification training. A contemporary trained general dentist delivers between 3,000 and 4,000 injections at multiple sites intra and extra orally during 4 years of prequalification training. During the first 4 years of medical training, a medical student will give less than 50 injections, which are usually given into large joints or to laceration edges for sutures. In a 3-year or 4-year medical resident training program (family practice, internal medicine, surgical specialties) residents administer considerably less than 3000 to 4000 injections. Both medical and dental students receive comprehensive pharmacology and physiology courses. Many clinical training institutions provide yearly resuscitation courses to maintain updated certifications (Table 2).

Discussion

Historically, many of the neuromuscular pathologies presented to general dentists have been treated surgically by medical physicians, which included oral maxillofacial specialists. BoNTA has proven to be an effective method for therapeutic treatment of many pathologies intra and extra orally.

Botox has been used by head and neck clinicians to treat migraine headaches (Binder et al). Using Botox as part of the arsenal for a dentist would include treatment of headaches or migraines when related to TMD. Therefore, being aware of the classically described sites to inject Botox for migraines would be advantageous: 1. Glabella, 2. Temporal, 3. Forehead Temporal, 4. Forehead, 5. Occipital, and 6. Suboccipital. The drawback for dentists to treat headaches is that they do not receive training about signs, symptoms and differential diagnosis of brain tumors or space occupying lesions. If the headache is due to TMD, they could use Botox to treat accordingly. Implants and other surgical procedures can aid the integrity of the intraoral architecture and maintain the orientation of hard and soft tissues. BoNTA can be administered for extra oral aesthetics to compliment one’s oral-to-face relationships. A compromise would be to allow the general dentist to provide BoNTA injections limited by anatomical boundaries. The authors suggest that injections are limited to the neck and face at or below the infra orbital rims and temporal regions.

There doesn’t appear to be an obvious set of criteria within the healthcare profession to determine who can administer BoNTA injections. The results of this study revealed that a dentally trained clinician has appropriate knowledge and training in the basic sciences and clinical skills compared to contemporary medically trained physicians, which enable them to administer BoNTA injections safely. In order to police a high standard of care and safety, governing boards that decide on which healthcare providers are allowed privileges to administer BoNTA injections could demand regular continuing dental/medical education courses. This would ensure safe treatment to patients and maintain high delivery standards by updating the clinician’s basic science knowledge and clinical skill level. Dental trainees receive more didactic training of the head and neck region and develop a more extensive repertoire of injection techniques during their training compared to contemporary medical school trainees. Specialty clinics, such as Oral Maxillofacial surgery, are being inundated by patients presenting with facial pain generally treated with BoNTA therapy. Many Oral Maxillofacial surgeons would be grateful if the responsibility for BoNTA injection was shared with their general dentist colleagues. This would allow Oral Maxillofacial surgeons to see potential surgical conditions in a more timely manner, thus better utilizing their specialized training.

Conclusion

This study revealed the training of a general dentist appears to satisfy the basic science knowledge and clinical skills one would need to administer BoNTA injections to the head and neck region.
References

1. Erbguth FJ (2004) Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord 19: S2-S6.

2. Tan EK, Jankovic J (2000) Treating severe Bruxism with botulinum toxin. J Am Dent Assoc 131: 211-216.

3. Tan EK, Jankovic J (1999) Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 53: 2102-2107.

4. Laskawi, R., Rohrbach S (2001) Oromandibular dystonia. Clinical forms, diagnosis and examples of therapy with botulinum toxin. Laryngorhinootologie 80: 708-713.

5. Clark GT (2003) The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin. Phys Med Rehabil Clin N Am 14: 727-748.

6. Ellis M, Gottstein U, Rohrbach-Volland S, Arglebe C, Laskawi R (2004) Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas and sialadenitis. Laryngoscope 114: 1856-1860.

7. Ellis M, Laskawi R, Rohrbach-Volland S, Arglebe C, Beuche W (2002) Botulinum toxin to reduce saliva flow: selected indications for ultrasound-guided toxin application into salivary glands. Laryngoscope 112: 82-86.

8. Katz H (2005) Botulinum toxins in dentistry - the new paradigm for masticatory muscle hyperactivity. Singapore Dent J 27: 7-12.

9. Chikhani L, Dichamp J (2003) Bruxism, tempromandibular dysfunction and botulinum toxin. Ann Readapt Med Phys 46: 333-337.

10. Defazio G, Abbruzzese G, Girlanda P, Vacca L, Currà A, et al. (2002) Botulinum Toxin A Treatment for Primary Hemifacial Spasm: a 10-year multicenter study. Arch Neurol 59:418-420.

11. Freund B, Schwartz M, Symington JM (2000) Botulinum toxin: new treatment for tempromandibular disorders. Br J Oral Maxillofac Surg 38: 466-471.

12. Yoshida K, Iizuka T (2006) Botulinum toxin treatment for upper airway collapse resulting from tempromandibular joint dislocation due to jaw-opening dystonia. Cranio 24: 217-222.

13. Song PC, Schwartz J, Blitzer A (2007) The emerging role of botulinum toxin in the treatment of tempromandibular disorders. Oral Dis 13: 253-260.

14. Jankovic J (2009) Disease-oriented approach to botulinum toxin use. Toxicon 54: 614-623.

15. Dowson AJ, Kilminster SG, Salt R (2008) Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting. Drugs R D 9: 147-158.

16. Marko A, Susan R (2008) Orofacial Pain and Neurological Disorders Affecting the Head and Neck. Improving Oral Health for the Elderly 17: 369-392.

17. Balasubramaniam R, Rasmusen J, Carlson LW, Van Sickels JE, Okeson JP (2008) Oromandibular dystonia revisited: a review and a unique case. J Oral Maxillofac Surg 66: 379-386.

18. Bakke M, Moller E, Werdelin LM, Dalager T, Kilai N, et al. (2005) Treatment of severe tempromandibular joint clicking with botulinum toxin in the lateral pterygoid muscles in two cases of anterior disc displacement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100: 693-700.

19. National Institute of dental and craniofacial research. (2008).

20. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM (2000) Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 123: 669-676.

21. Hoque A, McAndrew M (2009) Use of botulinum toxin in dentistry. N Y State Dent J 75: 52-55.